Allianz Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Allianz Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,200	Closed	-$1.31M	–	2313
2023 Q1	$1.31M	Buy	12,200 +700	+6%	+$80.6K	﹤0.01%	1556
2022 Q4	$1.26M	Hold	11,500	–	–	﹤0.01%	1435
2022 Q3	$679K	Sell	11,500 -49,633	-81%	-$2.27M	﹤0.01%	1487
2022 Q2	$1.73M	Buy	61,133 +27,998	+84%	+$812K	﹤0.01%	1471
2022 Q1	$1.25M	Buy	33,135 +22,065	+199%	+$872K	﹤0.01%	1766
2021 Q4	$438K	Buy	+11,070	New	+$347K	﹤0.01%	2256

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Allianz Asset Management's RXDX Position: Q2 2023 in Review

Allianz Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 12,200 shares — an estimated $1.31M sold.

Allianz Asset Management first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $1.73M in Q2 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Allianz Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Allianz Asset Management sold 12,200 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.31M.
Allianz Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Allianz Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $1.73M in Q2 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Allianz Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.